Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1993 1
1995 3
1996 4
1997 19
1998 16
1999 27
2000 31
2001 50
2002 34
2003 33
2004 40
2005 46
2006 47
2007 84
2008 113
2009 132
2010 152
2011 186
2012 165
2013 187
2014 178
2015 152
2016 188
2017 205
2018 155
2019 150
2020 171
2021 133
2022 86
2023 69
2024 74

Text availability

Article attribute

Article type

Publication date

Search Results

2,674 results

Results by year

Filters applied: Free full text. Clear all
Page 1
Risk of tuberculosis after initiation of antiretroviral therapy among persons with HIV in Europe.
Johansen IS, Roen A, Kraef C, Martín-Iguacel R, Nemeth J, Fenner L, Zangerle R, Llibre JM, Miller RF, Suarez I, de Wit S, Wit F, Mussini C, Saracino A, Canetti D, Volny-Anne A, Jaschinski N, Neesgaard B, Ryom L, Peters L, Garges HP, Rooney JF, Podlekareva D, Mocroft A, Kirk O; RESPOND Study group. Johansen IS, et al. Int J Infect Dis. 2024 Oct;147:107199. doi: 10.1016/j.ijid.2024.107199. Epub 2024 Aug 13. Int J Infect Dis. 2024. PMID: 39142437 Free article.
Twelve-month effectiveness and safety of bictegravir/emtricitabine/tenofovir alafenamide in treatment-naïve and treatment-experienced people with HIV: Findings from the Asia cohort of the BICSTaR study.
Tseng YT, Yang CJ, Kim YS, Choi JY, Wong CS, Lee KY, Lee JA, Chang J, Harrison R, Marongiu A, Lee SH, Hung CC. Tseng YT, et al. J Microbiol Immunol Infect. 2024 Oct;57(5):760-770. doi: 10.1016/j.jmii.2024.07.003. Epub 2024 Jul 14. J Microbiol Immunol Infect. 2024. PMID: 39079772 Free article.
An observational cohort study to investigate the impact of dolutegravir in pregnancy and its obesogenic effects on the metabolic health of women living with HIV and their children: Study protocol.
Abrams EJ, Jao J, Madlala HP, Zerbe A, Catalano P, Gerschenson M, Goedecke JH, Gomba Y, Josefson J, Kurland IJ, Legbedze J, McComsey GA, Matyesini S, Mukonda E, Robinson D, Myer L. Abrams EJ, et al. PLoS One. 2024 Aug 19;19(8):e0307296. doi: 10.1371/journal.pone.0307296. eCollection 2024. PLoS One. 2024. PMID: 39159183 Free PMC article.
Metabolic, Mitochondrial, and Inflammatory Effects of Efavirenz, Emtricitabine, and Tenofovir Disoproxil Fumarate in Asymptomatic Antiretroviral-Naïve People with HIV.
Barroso S, Guitart-Mampel M, García-García FJ, Cantó-Santos J, Valls-Roca L, Andújar-Sánchez F, Vilaseca-Capel A, Tobías E, Arias-Dimas A, Quesada-López T, Artuch R, Villarroya F, Giralt M, Martínez E, Lozano E, Garrabou G. Barroso S, et al. Int J Mol Sci. 2024 Aug 1;25(15):8418. doi: 10.3390/ijms25158418. Int J Mol Sci. 2024. PMID: 39125986 Free PMC article.
Clinical Efficacy of the HIV Protease Inhibitor Indinavir in Combination with Chemotherapy for Advanced Classic Kaposi Sarcoma Treatment: A Single-Arm, Phase II Trial in the Elderly.
Sgadari C, Scoppio B, Picconi O, Tripiciano A, Gaiani FM, Francavilla V, Arancio A, Campagna M, Palladino C, Moretti S, Monini P, Brambilla L, Ensoli B. Sgadari C, et al. Cancer Res Commun. 2024 Aug 1;4(8):2112-2122. doi: 10.1158/2767-9764.CRC-24-0102. Cancer Res Commun. 2024. PMID: 39028943 Free PMC article. Clinical Trial.
Efficacy, Safety, and Pharmacokinetics by Body Mass Index Category in Phase 3/3b Long-Acting Cabotegravir Plus Rilpivirine Trials.
Elliot ER, Polli JW, Patel P, Garside L, Grove R, Barnett V, Roberts J, Byrapuneni S, Crauwels H, Ford SL, Van Solingen-Ristea R, Birmingham E, D'Amico R, Baugh B, van Wyk J. Elliot ER, et al. J Infect Dis. 2024 Jul 25;230(1):e34-e42. doi: 10.1093/infdis/jiad580. J Infect Dis. 2024. PMID: 39052748 Free PMC article. Clinical Trial.
AKI in a Patient with Treated HIV Infection.
Kuruvada KM, DiFranza L, Fisher M. Kuruvada KM, et al. Kidney360. 2024 Jul 1;5(7):1065-1066. doi: 10.34067/KID.0000000000000480. Kidney360. 2024. PMID: 39052475 Free PMC article. No abstract available.
Long-term impact of immediate versus deferred antiretroviral therapy on kidney health in people with HIV.
Pelchen-Matthews A, Mocroft A, Ryom L, Ross MJ, Sharma S, Coca S, Achhra A, Cornell E, Tracy R, Phillips A, Alonso MM, Toulomi G, Agan BK, Medland N, Wyatt CM; INSIGHT START Study Group. Pelchen-Matthews A, et al. Kidney Int. 2024 Jul;106(1):136-144. doi: 10.1016/j.kint.2024.04.010. Epub 2024 May 1. Kidney Int. 2024. PMID: 38697479 Free PMC article. Clinical Trial.
Assessment of weight gain in adult patients living with HIV receiving first-line dolutegravir-based or efavirenz-based ART regimens in routine care clinics in Tshwane district, South Africa: An observational study.
Sawry S, Ayalew K, Maimela G, Briggs-Hagen M, van Wyk-Heath M, Mthethwa S, Shai S, Mngomezulu NN, Tlhowe L, Achere-Darko J, Bedford J, Martin CE, Fairlie L, Imrie J. Sawry S, et al. HIV Med. 2024 Jul;25(7):826-839. doi: 10.1111/hiv.13638. Epub 2024 Mar 22. HIV Med. 2024. PMID: 38520085 Free PMC article.
Phase 1 randomized trials to assess safety, pharmacokinetics, and vaginal bleeding associated with use of extended duration dapivirine and levonorgestrel vaginal rings.
Achilles SL, Kelly CW, Hoesley CJ, Blithe DL, Brown J, Richardson BA, Devlin B, Hendrix CW, Poloyac SM, Marzinke MA, Gundacker H, Singh D, Piper JM, Johnson S, Steytler J, Chen BA; MTN-030/IPM 041 and MTN-044/IPM 053/CCN019 Protocol Teams for the Microbicide Trials Network and the Contraceptive Clinical Trials Network. Achilles SL, et al. PLoS One. 2024 Jun 5;19(6):e0304552. doi: 10.1371/journal.pone.0304552. eCollection 2024. PLoS One. 2024. PMID: 38838028 Free PMC article. Clinical Trial.
Efficacy and safety of three antiretroviral therapy regimens for treatment-naive African adults living with HIV-2 (FIT-2): a pilot, phase 2, non-comparative, open-label, randomised controlled trial.
Eholie SP, Ekouevi DK, Chazallon C, Charpentier C, Messou E, Diallo Z, Zoungrana J, Minga A, Ngom Gueye NF, Hawerlander D, Dembele F, Colin G, Tchounga B, Karcher S, Le Carrou J, Tchabert-Guié A, Toni TD, Ouédraogo AS, Bado G, Toure Kane C, Seydi M, Poda A, Mensah E, Diallo I, Drabo YJ, Anglaret X, Brun-Vezinet F; FIT-2 study group. Eholie SP, et al. Lancet HIV. 2024 Jun;11(6):e380-e388. doi: 10.1016/S2352-3018(24)00085-7. Epub 2024 May 10. Lancet HIV. 2024. PMID: 38740027 Free article. Clinical Trial.
Switch to bictegravir/emtricitabine/tenofovir alafenamide from dolutegravir-based therapy.
Orkin C, Antinori A, Rockstroh JK, Moreno-Guillén S, Martorell CT, Molina JM, Lazzarin A, Maggiolo F, Yazdanpanah Y, Andreatta K, Huang H, Hindman JT, Martin H, Pozniak A. Orkin C, et al. AIDS. 2024 Jun 1;38(7):983-991. doi: 10.1097/QAD.0000000000003865. Epub 2024 Feb 21. AIDS. 2024. PMID: 38349226 Free PMC article. Clinical Trial.
Long-term safety and impact of immune recovery in heavily treatment-experienced adults receiving fostemsavir for up to 5 years in the phase 3 BRIGHTE study.
Llibre JM, Aberg JA, Walmsley S, Velez J, Zala C, Crabtree Ramírez B, Shepherd B, Shah R, Clark A, Tenorio AR, Pierce A, Du F, Li B, Wang M, Chabria S, Warwick-Sanders M. Llibre JM, et al. Front Immunol. 2024 May 28;15:1394644. doi: 10.3389/fimmu.2024.1394644. eCollection 2024. Front Immunol. 2024. PMID: 38863717 Free PMC article. Clinical Trial.
Associations between change in BMI and the risk of hypertension and dyslipidaemia in people receiving integrase strand-transfer inhibitors, tenofovir alafenamide, or both compared with other contemporary antiretroviral regimens: a multicentre, prospective observational study from the RESPOND consortium cohorts.
Byonanebye DM, Polizzotto MN, Maltez F, Rauch A, Grabmeier-Pfistershammer K, Wit F, De Wit S, Castagna A, d'Arminio Monforte A, Mussini C, Wasmuth JC, Fontas E, Abela I, Sarcletti M, Bansi-Matharu L, Jaschinski N, Peters L, Hosein SR, Vannappagari V, Cohen C, Bissio E, Mocroft A, Law M, Ryom L, Petoumenos K; RESPOND study group. Byonanebye DM, et al. Lancet HIV. 2024 May;11(5):e321-e332. doi: 10.1016/S2352-3018(23)00328-4. Epub 2024 Apr 12. Lancet HIV. 2024. PMID: 38621392 Free PMC article.
Comparison of safety and effectiveness of antiretroviral therapy regimens among pregnant women living with HIV at preconception or during pregnancy: a systematic review and network meta-analysis of randomized trials.
Mehrabi F, Karamouzian M, Farhoudi B, Moradi Falah Langeroodi S, Mehmandoost S, Abbaszadeh S, Motaghi S, Mirzazadeh A, Sadeghirad B, Sharifi H. Mehrabi F, et al. BMC Infect Dis. 2024 Apr 19;24(1):417. doi: 10.1186/s12879-024-09303-2. BMC Infect Dis. 2024. PMID: 38641597 Free PMC article.
Risk of Cardiovascular Events in People with HIV (PWH) Treated with Integrase Strand-Transfer Inhibitors: The Debate Is Not Over; Results of the SCOLTA Study.
Corti N, Menzaghi B, Orofino G, Guastavigna M, Lagi F, Di Biagio A, Taramasso L, De Socio GV, Molteni C, Madeddu G, Salomoni E, Pellicanò GF, Pontali E, Bellagamba R, Celesia BM, Cascio A, Sarchi E, Gulminetti R, Calza L, Maggi P, Cenderello G, Bandera A, Carleo MA, Falasca K, Ferrara S, Martini S, Guadagnino G, Angioni G, Bargiacchi O, Ricci ED, Squillace N, Bonfanti P. Corti N, et al. Viruses. 2024 Apr 15;16(4):613. doi: 10.3390/v16040613. Viruses. 2024. PMID: 38675955 Free PMC article.
Measures of Longitudinal Immune Dysfunction and Risk of AIDS and Non-AIDS Defining Malignancies in Antiretroviral-Treated People With Human Immunodeficiency Virus.
Chammartin F, Mocroft A, Egle A, Zangerle R, Smith C, Mussini C, Wit F, Vehreschild JJ, d'Arminio Monforte A, Castagna A, Bailly L, Bogner J, de Wit S, Matulionyte R, Law M, Svedhem V, Tallada J, Garges HP, Marongiu A, Borges ÁH, Jaschinski N, Neesgaard B, Ryom L, Bucher HC; RESPOND Study Group. Chammartin F, et al. Clin Infect Dis. 2024 Apr 10;78(4):995-1004. doi: 10.1093/cid/ciad671. Clin Infect Dis. 2024. PMID: 38092042 Free PMC article.
Efficacy and safety of switching to dolutegravir/lamivudine in virologically suppressed people with HIV-1 aged ≥ 50 years: week 48 pooled results from the TANGO and SALSA studies.
Walmsley S, Smith DE, Górgolas M, Cahn PE, Lutz T, Lacombe K, Kumar PN, Wynne B, Grove R, Bontempo G, Moodley R, Okoli C, Kisare M, Jones B, Clark A, Ait-Khaled M. Walmsley S, et al. AIDS Res Ther. 2024 Mar 21;21(1):17. doi: 10.1186/s12981-024-00604-9. AIDS Res Ther. 2024. PMID: 38515183 Free PMC article.
Bone turnover change after randomized switch from tenofovir disoproxil to tenofovir alafenamide fumarate in men with HIV.
Moore AEB, Burns JE, Sally D, Milinkovic A, Krokos G, John J, Rookyard C, Borca A, Pool ERM, Tostevin A, Harman A, Dulnoan DS, Gilson R, Arenas-Pinto A, Cook GJR, Saunders J, Dunn D, Blake GM, Pett SL. Moore AEB, et al. AIDS. 2024 Mar 15;38(4):521-529. doi: 10.1097/QAD.0000000000003811. Epub 2024 Feb 1. AIDS. 2024. PMID: 38061030 Free PMC article. Clinical Trial.
DOLAMA 200: Effectiveness and Safety of a Dual Therapy with Dolutegravir Plus Lamivudine in Treatment-Experienced HIV-1 Infected Real World Participants in Spain.
Sequera-Arquelladas S, Hidalgo-Tenorio C, López-Cortés L, Gutiérrez A, Santos J, Téllez F, Omar M, Ferra-Murcia S, Fernández E, Javier R, García-Vallecillos C, Pasquau J. Sequera-Arquelladas S, et al. Viruses. 2024 Feb 6;16(2):259. doi: 10.3390/v16020259. Viruses. 2024. PMID: 38400035 Free PMC article.
Natural course of AIDS following HIV-2 infection.
Fuhr H, Christopeit M. Fuhr H, et al. Infection. 2024 Feb;52(1):275-276. doi: 10.1007/s15010-023-02143-3. Epub 2023 Dec 12. Infection. 2024. PMID: 38085491 Free PMC article.
Characterization and outcomes of difficult-to-treat patients starting modern first-line ART regimens: Data from the ICONA cohort.
Gagliardini R, Tavelli A, Rusconi S, Lo Caputo S, Spagnuolo V, Santoro MM, Costantini A, Vergori A, Maggiolo F, Giacomelli A, Burastero G, Madeddu G, Quiros Roldan E, d'Arminio Monforte A, Antinori A, Cozzi-Lepri A; ICONA Foundation Study Group. Gagliardini R, et al. Int J Antimicrob Agents. 2024 Jan;63(1):107018. doi: 10.1016/j.ijantimicag.2023.107018. Epub 2023 Oct 29. Int J Antimicrob Agents. 2024. PMID: 38214244 Free article.
Efficacy and safety of long-acting cabotegravir compared with daily oral tenofovir disoproxil fumarate plus emtricitabine to prevent HIV infection in cisgender men and transgender women who have sex with men 1 year after study unblinding: a secondary analysis of the phase 2b and 3 HPTN 083 randomised controlled trial.
Landovitz RJ, Hanscom BS, Clement ME, Tran HV, Kallas EG, Magnus M, Sued O, Sanchez J, Scott H, Eron JJ, Del Rio C, Fields SD, Marzinke MA, Eshleman SH, Donnell D, Spinelli MA, Kofron RM, Berman R, Piwowar-Manning EM, Richardson PA, Sullivan PA, Lucas JP, Anderson PL, Hendrix CW, Adeyeye A, Rooney JF, Rinehart AR, Cohen MS, McCauley M, Grinsztejn B; HPTN 083 Study Team. Landovitz RJ, et al. Lancet HIV. 2023 Dec;10(12):e767-e778. doi: 10.1016/S2352-3018(23)00261-8. Epub 2023 Nov 9. Lancet HIV. 2023. PMID: 37952550 Free PMC article. Clinical Trial.
Integrase strand-transfer inhibitor use and cardiovascular events in adults with HIV: an emulation of target trials in the HIV-CAUSAL Collaboration and the Antiretroviral Therapy Cohort Collaboration.
Rein SM, Lodi S, Logan RW, Touloumi G, Antoniadou A, Wittkop L, Bonnet F, van Sighem A, van der Valk M, Reiss P, Klein MB, Young J, Jarrin I, d'Arminio Monforte A, Tavelli A, Meyer L, Tran L, Gill MJ, Lang R, Surial B, Haas AD, Justice AC, Rentsch CT, Phillips A, Sabin CA, Miro JM, Trickey A, Ingle SM, Sterne JAC, Hernán MA; Antiretroviral Therapy Cohort Collaboration and the HIV-CAUSAL Collaboration. Rein SM, et al. Lancet HIV. 2023 Nov;10(11):e723-e732. doi: 10.1016/S2352-3018(23)00233-3. Lancet HIV. 2023. PMID: 37923486 Free article.
Impact of Integrase Inhibitors on Cardiovascular Disease Events in People With Human Immunodeficiency Virus Starting Antiretroviral Therapy.
Surial B, Chammartin F, Damas J, Calmy A, Haerry D, Stöckle M, Schmid P, Bernasconi E, Fux CA, Tarr PE, Günthard HF, Wandeler G, Rauch A; Swiss HIV Cohort Study. Surial B, et al. Clin Infect Dis. 2023 Sep 11;77(5):729-737. doi: 10.1093/cid/ciad286. Clin Infect Dis. 2023. PMID: 37157869 Free PMC article. Clinical Trial.
Real-life safety of Emtricitabine/Tenofovir Alafenamide/Bictegravir.
Squillace N, Ricci E, Maggi P, Taramasso L, Menzaghi B, De Socio GV, Piconi S, Maurizio Celesia B, Orofino G, Sarchi E, Pellicanò GF, Simeone F, Valsecchi L, Bandera A, Cenderello G, Attala L, Angioni G, Falasca K, Cascio A, Bargiacchi O, Di Biagio A, Bonfanti P; CISAI Study Group. Squillace N, et al. PLoS One. 2023 Aug 9;18(8):e0289132. doi: 10.1371/journal.pone.0289132. eCollection 2023. PLoS One. 2023. PMID: 37556481 Free PMC article.
Efficacy, durability, and tolerability of bictegravir/emtricitabine/tenofovir alafenamide for the treatment of HIV in a real-world setting in Belgium.
Nasreddine R, Florence E, Yombi JC, Henrard S, Darcis G, Van Praet J, Vandekerckhove L, Allard SD, Demeester R, Messiaen P, Ausselet N, Delforge M, De Wit S; Belgian Research on AIDS and HIV Consortium (BREACH). Nasreddine R, et al. HIV Med. 2023 Aug;24(8):914-924. doi: 10.1111/hiv.13493. Epub 2023 Apr 10. HIV Med. 2023. PMID: 37038245 Free article.
Pharmacogenetics of tenofovir renal toxicity in HIV-positive Southern Africans.
Mateza S, Bradford Y, Maartens G, Sokhela S, Chandiwana NC, Venter WDF, Post FA, Ritchie MD, Haas DW, Sinxadi P. Mateza S, et al. Pharmacogenet Genomics. 2023 Jul 1;33(5):91-100. doi: 10.1097/FPC.0000000000000491. Epub 2023 Apr 24. Pharmacogenet Genomics. 2023. PMID: 37099271 Free PMC article. Clinical Trial.
Realizing the Promise of Dolutegravir in Effectively Treating Children and Adolescents Living With HIV in Real-world Settings in 6 Countries in Eastern and Southern Africa.
Bacha JM, Dlamini S, Anabwani F, Gwimile J, Kanywa JB, Farirai J, Bvumbwe M, Tsotako M, Steffy T, Nguyen D, Mendez-Reyes JE, Elyanu P, Haq H. Bacha JM, et al. Pediatr Infect Dis J. 2023 Jul 1;42(7):576-581. doi: 10.1097/INF.0000000000003878. Epub 2023 Feb 14. Pediatr Infect Dis J. 2023. PMID: 36795586 Free PMC article.
Renal profile of patients treated with elvitegravir/cobicistat/emtricitabine/tenofovir alafenamide fumarate and dolutegravir/abacavir/lamivudine: 120-week results from a real-world cohort.
Rotea-Salvo S, Martínez-Pradeda A, Fernández-Oliveira C, Giménez-Arufe V, Balboa-Barreiro V, Margusino-Framiñán L, Mena-De-Cea Á, Vázquez-Rodríguez P, Castro-Iglesias Á, López-Calvo S, Martín-Herranz I, Míguez-Rey E, Cid-Silva P. Rotea-Salvo S, et al. Eur J Hosp Pharm. 2023 Jul;30(4):221-226. doi: 10.1136/ejhpharm-2021-002896. Epub 2021 Oct 14. Eur J Hosp Pharm. 2023. PMID: 34649965 Free PMC article.
Efficacy and safety of three antiretroviral therapy regimens started in pregnancy up to 50 weeks post partum: a multicentre, open-label, randomised, controlled, phase 3 trial.
Chinula L, Ziemba L, Brummel S, McCarthy K, Coletti A, Krotje C, Johnston B, Knowles K, Moyo S, Stranix-Chibanda L, Hoffman R, Sax PE, Stringer J, Chakhtoura N, Jean-Philippe P, Korutaro V, Cassim H, Fairlie L, Masheto G, Boyce C, Frenkel LM, Amico KR, Purdue L, Shapiro R, Mmbaga BT, Patel F, van Wyk J, Rooney JF, Currier JS, Lockman S; IMPAACT 2010/VESTED Study Team and Investigators. Chinula L, et al. Lancet HIV. 2023 Jun;10(6):e363-e374. doi: 10.1016/S2352-3018(23)00061-9. Epub 2023 May 8. Lancet HIV. 2023. PMID: 37167996 Free PMC article. Clinical Trial.
Effectiveness and tolerability of dolutegravir/lamivudine for the treatment of HIV-1 infection in clinical practice.
Suárez-García I, Alejos B, Hernando V, Viñuela L, Vera García M, Rial-Crestelo D, Pérez Elías MJ, Albendín Iglesias H, Peraire J, Tiraboschi J, Díaz A, Moreno S, Jarrín I; Cohort of the Spanish HIV/AIDS Research Network (CoRIS). Suárez-García I, et al. J Antimicrob Chemother. 2023 Jun 1;78(6):1423-1432. doi: 10.1093/jac/dkad102. J Antimicrob Chemother. 2023. PMID: 37099559 Free PMC article.
Integrase Inhibitors are Associated with Neuropsychiatric Symptoms in Women with HIV.
Rubin LH, O'Halloran JA, Williams DW, Li Y, Fitzgerald KC, Dastgheyb R, Damron AL, Maki PM, Spence AB, Sharma A, Gustafson DR, Milam J, Weber KM, Adimora AA, Ofotokun I, Fischl MA, Konkle-Parker D, Xu Y. Rubin LH, et al. J Neuroimmune Pharmacol. 2023 Jun;18(1-2):1-8. doi: 10.1007/s11481-021-10042-3. Epub 2022 Feb 17. J Neuroimmune Pharmacol. 2023. PMID: 35178611 Free PMC article.
Immune Reconstitution and Safe Metabolic Profile after the Switch to Bictegravir/Emtricitabine/Tenofovir Alafenamide Fumarate among Virologically Controlled PLWH: A 96 Week Update from the BICTEL Cohort.
Lazzaro A, Bianchini D, Gentilini Cacciola E, Mezzaroma I, Falciano M, Andreoni C, Fimiani C, Santinelli L, Maddaloni L, Bugani G, Ceccarelli G, Mastroianni CM, d'Ettorre G. Lazzaro A, et al. Viruses. 2023 May 23;15(6):1222. doi: 10.3390/v15061222. Viruses. 2023. PMID: 37376522 Free PMC article.
Long-Acting Cabotegravir and Rilpivirine Dosed Every 2 Months in Adults With Human Immunodeficiency Virus 1 Type 1 Infection: 152-Week Results From ATLAS-2M, a Randomized, Open-Label, Phase 3b, Noninferiority Study.
Overton ET, Richmond G, Rizzardini G, Thalme A, Girard PM, Wong A, Porteiro N, Swindells S, Reynes J, Noe S, Harrington C, Español CM, Acuipil C, Aksar A, Wang Y, Ford SL, Crauwels H, van Eygen V, Van Solingen-Ristea R, Latham CL, Thiagarajah S, D'Amico R, Smith KY, Vandermeulen K, Spreen WR. Overton ET, et al. Clin Infect Dis. 2023 May 3;76(9):1646-1654. doi: 10.1093/cid/ciad020. Clin Infect Dis. 2023. PMID: 36660819 Free PMC article. Clinical Trial.
A phase I study to assess safety, pharmacokinetics, and pharmacodynamics of a vaginal insert containing tenofovir alafenamide and elvitegravir.
Thurman AR, Ouattara LA, Yousefieh N, Anderson PL, Bushman LR, Fang X, Hanif H, Clark M, Singh O, Doncel GF. Thurman AR, et al. Front Cell Infect Microbiol. 2023 Apr 19;13:1130101. doi: 10.3389/fcimb.2023.1130101. eCollection 2023. Front Cell Infect Microbiol. 2023. PMID: 37153145 Free PMC article. Clinical Trial.
Blood glucose trajectories and incidence of diabetes mellitus in Ugandan people living with HIV initiated on dolutegravir.
Mulindwa F, Castelnuovo B, Brusselaers N, Bollinger R, Rhein J, Edrisa M, Buzibye A, Amutuhaire W, Yendewa G, Nabaggala S, Odongpiny ELA, Kiguba R, Nakawooza A, Dujanga S, Nabwana M, Schwarz JM. Mulindwa F, et al. AIDS Res Ther. 2023 Mar 13;20(1):15. doi: 10.1186/s12981-023-00510-6. AIDS Res Ther. 2023. PMID: 36915103 Free PMC article.
Pharmacokinetics, Tolerability, and Safety of Doravirine and Doravirine/Lamivudine/Tenofovir Disoproxil Fumarate Fixed-Dose Combination Tablets in Adolescents Living With HIV: Week 24 Results From IMPAACT 2014.
Melvin AJ, Yee KL, Gray KP, Yedla M, Wan H, Tobin NH, Teppler H, Campbell H, McCarthy K, Scheckter R, Aurpibul L, Ounchanum P, Rungmaitree S, Cassim H, McFarland E, Flynn P, Cooper E, Krotje C, Townley E, Moye J, Best BM; IMPAACT 2014 study team. Melvin AJ, et al. J Acquir Immune Defic Syndr. 2023 Feb 1;92(2):153-161. doi: 10.1097/QAI.0000000000003116. J Acquir Immune Defic Syndr. 2023. PMID: 36215957 Free PMC article.
Safety and efficacy of switching to elvitegravir, cobicistat, emtricitabine, tenofovir disoproxil fumarate in treatment-experienced people with HIV: a multicenter cohort study.
De Castro N, Brun A, Sellier P, Hamet G, Mechaï F, Garrait V, Chabrol A, Bouldouyre MA, Froguel E, Troisvallets D, Caraux-Paz P, Delaugerre C, Rozenbaum W, Molina JM. De Castro N, et al. AIDS Res Ther. 2023 Jan 3;20(1):1. doi: 10.1186/s12981-022-00499-4. AIDS Res Ther. 2023. PMID: 36597160 Free PMC article.
Exposure and virologic outcomes of dolutegravir combined with ritonavir boosted darunavir in treatment-naïve individuals enrolled in the Netherlands Cohort Study on Acute HIV infection (NOVA).
Prins HAB, Zino L, Svensson EM, Verbon A, de Bree GJ, Prins JM, Reiss P, Burger DM, Rokx C, Colbers A; NOVA Study Team. Prins HAB, et al. Int J Antimicrob Agents. 2023 Jan;61(1):106697. doi: 10.1016/j.ijantimicag.2022.106697. Epub 2022 Dec 2. Int J Antimicrob Agents. 2023. PMID: 36470510 Free article.
Bictegravir/emtricitabine/tenofovir alafenamide in older individuals with HIV: Results of a 96-week, phase 3b, open-label, switch trial in virologically suppressed people ≥65 years of age.
Maggiolo F, Rizzardini G, Molina JM, Pulido F, De Wit S, Vandekerckhove L, Berenguer J, D'Antoni ML, Blair C, Chuck SK, Piontkowsky D, Martin H, Haubrich R, McNicholl IR, Gallant J. Maggiolo F, et al. HIV Med. 2023 Jan;24(1):27-36. doi: 10.1111/hiv.13319. Epub 2022 May 8. HIV Med. 2023. PMID: 35527425 Free PMC article. Clinical Trial.
CD4:CD8 Ratio and CD8 Cell Count and Their Prognostic Relevance for Coronary Heart Disease Events and Stroke in Antiretroviral Treated Individuals: The Swiss HIV Cohort Study.
Chammartin F, Darling K, Abela IA, Battegay M, Furrer H, Calmy A, Bernasconi E, Schmid P, Hoffmann M, Bucher HC; and the Swiss HIV Cohort Study. Chammartin F, et al. J Acquir Immune Defic Syndr. 2022 Dec 15;91(5):508-515. doi: 10.1097/QAI.0000000000003094. Epub 2022 Sep 23. J Acquir Immune Defic Syndr. 2022. PMID: 36150371 Free PMC article.
Two-drug regimens for HIV treatment.
Gibas KM, Kelly SG, Arribas JR, Cahn P, Orkin C, Daar ES, Sax PE, Taiwo BO. Gibas KM, et al. Lancet HIV. 2022 Dec;9(12):e868-e883. doi: 10.1016/S2352-3018(22)00249-1. Epub 2022 Oct 26. Lancet HIV. 2022. PMID: 36309038 Free PMC article. Review.
48-Week effectiveness and tolerability of dolutegravir (DTG) + lamivudine (3TC) in antiretroviral-naïve adults living with HIV: A multicenter real-life cohort.
Cabello-Ubeda A, de Quirós JCLB, Martín Carbonero L, Sanz J, Vergas J, Mena Á, Torralba M, Hernández Segurado M, Pinto A, Tejerina F, Palmier E, Gutiérrez Á, Vázquez P, Pulido F, Górgolas M. Cabello-Ubeda A, et al. PLoS One. 2022 Nov 21;17(11):e0277606. doi: 10.1371/journal.pone.0277606. eCollection 2022. PLoS One. 2022. PMID: 36409695 Free PMC article.
Efficacy and Safety of Switching to Dolutegravir/Lamivudine Versus Continuing a Tenofovir Alafenamide-Based 3- or 4-Drug Regimen for Maintenance of Virologic Suppression in Adults Living With Human Immunodeficiency Virus Type 1: Results Through Week 144 From the Phase 3, Noninferiority TANGO Randomized Trial.
Osiyemi O, De Wit S, Ajana F, Bisshop F, Portilla J, Routy JP, Wyen C, Ait-Khaled M, Leone P, Pappa KA, Wang R, Wright J, George N, Wynne B, Aboud M, van Wyk J, Smith KY. Osiyemi O, et al. Clin Infect Dis. 2022 Sep 29;75(6):975-986. doi: 10.1093/cid/ciac036. Clin Infect Dis. 2022. PMID: 35079789 Free PMC article. Clinical Trial.
Once-daily dolutegravir-based antiretroviral therapy in infants and children living with HIV from age 4 weeks: results from the below 14 kg cohort in the randomised ODYSSEY trial.
Amuge P, Lugemwa A, Wynne B, Mujuru HA, Violari A, Kityo CM, Archary M, Variava E, White E, Turner RM, Shakeshaft C, Ali S, Nathoo KJ, Atwine L, Liberty A, Bbuye D, Kaudha E, Mngqibisa R, Mosala M, Mumbiro V, Nanduudu A, Ankunda R, Maseko L, Kekitiinwa AR, Giaquinto C, Rojo P, Gibb DM, Turkova A, Ford D; ODYSSEY Trial Team. Amuge P, et al. Lancet HIV. 2022 Sep;9(9):e638-e648. doi: 10.1016/S2352-3018(22)00163-1. Lancet HIV. 2022. PMID: 36055295 Free PMC article. Clinical Trial.
Dolutegravir in Pregnancy as Compared with Current HIV Regimens in the United States.
Patel K, Huo Y, Jao J, Powis KM, Williams PL, Kacanek D, Yee LM, Chadwick EG, Shiau S, Jacobson DL, Brummel SS, Sultan-Beyer L, Kahlert CR, Zash R, Seage GR 3rd; Pediatric HIV/AIDS Cohort Study; Swiss Mother and Child HIV Cohort Study. Patel K, et al. N Engl J Med. 2022 Sep 1;387(9):799-809. doi: 10.1056/NEJMoa2200600. N Engl J Med. 2022. PMID: 36053505 Free PMC article.
Brief Report: Evaluation of Inflammation and Atherogenesis Biomarkers Through 148 Weeks Postswitch to Dolutegravir and Rilpivirine in SWORD-1/SWORD-2.
Llibre JM, López Cortés LF, Aylott A, Wynne B, Matthews J, Van Solingen-Ristea R, Vandermeulen K, van Wyk J, Kahl LP. Llibre JM, et al. J Acquir Immune Defic Syndr. 2022 Sep 1;91(1):73-78. doi: 10.1097/QAI.0000000000003019. Epub 2022 May 11. J Acquir Immune Defic Syndr. 2022. PMID: 35551149 Free PMC article. Clinical Trial.
Incidence of hypertension in people with HIV who are treated with integrase inhibitors versus other antiretroviral regimens in the RESPOND cohort consortium.
Byonanebye DM, Polizzotto MN, Neesgaard B, Sarcletti M, Matulionyte R, Braun DL, Castagna A, de Wit S, Wit F, Fontas E, Vehreschild JJ, Vesterbacka J, Greenberg L, Hatleberg C, Garges H, Gallant J, Volny Anne A, Öllinger A, Mozer-Lisewska I, Surial B, Spagnuolo V, Necsoi C, van der Valk M, Mocroft A, Law M, Ryom L, Petoumenos K; RESPOND study group. Byonanebye DM, et al. HIV Med. 2022 Sep;23(8):895-910. doi: 10.1111/hiv.13273. Epub 2022 Mar 1. HIV Med. 2022. PMID: 35233903 Free PMC article.
Observational cohort study of rilpivirine (RPV) utilization in Europe.
Cozzi-Lepri A, Peters L, Pelchen-Matthews A, Neesgaard B, De Wit S, Johansen IS, Edwards S, Stephan C, Adamis G, Staub T, Zagalo A, Domingo P, Elbirt D, Kusejko K, Brännström J, Paduta D, Trofimova T, Szlavik J, Zilmer K, Losso M, Van Eygen V, Pai H, Lundgren J, Mocroft A; EuroSIDA Study Group. Cozzi-Lepri A, et al. AIDS Res Ther. 2022 Aug 6;19(1):38. doi: 10.1186/s12981-022-00457-0. AIDS Res Ther. 2022. PMID: 35933352 Free PMC article.
72 weeks post-partum follow-up of dolutegravir versus efavirenz initiated in late pregnancy (DolPHIN-2): an open-label, randomised controlled study.
Malaba TR, Nakatudde I, Kintu K, Colbers A, Chen T, Reynolds H, Read L, Read J, Stemmet LA, Mrubata M, Byrne K, Seden K, Twimukye A, Theunissen H, Hodel EM, Chiong J, Hu NC, Burger D, Wang D, Byamugisha J, Alhassan Y, Bokako S, Waitt C, Taegtmeyer M, Orrell C, Lamorde M, Myer L, Khoo S; DolPHIN-2 Study Group. Malaba TR, et al. Lancet HIV. 2022 Aug;9(8):e534-e543. doi: 10.1016/S2352-3018(22)00173-4. Lancet HIV. 2022. PMID: 35905752 Free article. Clinical Trial.
Maternal and infant renal safety following tenofovir disoproxil fumarate exposure during pregnancy in a randomized control trial.
Baltrusaitis K, Makanani B, Tierney C, Fowler MG, Moodley D, Theron G, Nyakudya LH, Tomu M, Fairlie L, George K, Heckman B, Knowles K, Browning R, Siberry GK, Taha TE, Stranix-Chibanda L; PROMISE P1084s Study Team. Baltrusaitis K, et al. BMC Infect Dis. 2022 Jul 20;22(1):634. doi: 10.1186/s12879-022-07608-8. BMC Infect Dis. 2022. PMID: 35858874 Free PMC article. Clinical Trial.
Approaches to accelerating the study of new antiretrovirals in pregnancy.
Abrams EJ, Calmy A, Fairlie L, Mahaka IC, Chimula L, Flynn PM, Kinuthia J, Myer L, Khoo SH, Musoke P, Zwerski S, Zech JM, Lockman S, Siberry GK. Abrams EJ, et al. J Int AIDS Soc. 2022 Jul;25 Suppl 2(Suppl 2):e25916. doi: 10.1002/jia2.25916. J Int AIDS Soc. 2022. PMID: 35851757 Free PMC article.
Class-Based Antiretroviral Exposure and Cognition Among Women Living with HIV.
Spence AB, Liu C, Rubin L, Aouizerat B, Vance DE, Bolivar H, Lahiri CD, Adimora AA, Weber K, Gustafson D, Sosanya O, Turner RS, Kassaye S. Spence AB, et al. AIDS Res Hum Retroviruses. 2022 Jul;38(7):561-570. doi: 10.1089/AID.2021.0097. Epub 2022 Mar 2. AIDS Res Hum Retroviruses. 2022. PMID: 35109713 Free PMC article.
Dolutegravir plus rilpivirine: benefits beyond viral suppression: DORIPEX retrospective study.
Troya J, Dueñas C, Irazola I, de Los Santos I, de la Fuente S, Gil D, Hernández C, Galindo MJ, Gómez J, Delgado E, Moreno-García E, Pousada G, Aldámiz T, Iribarren JA, Guerra JM, Morán MÁ, Galera C, De La Fuente J, Peláez A, Cervero M, Garcinuño M, Montero M, Ceballos F, Buzón L; on behalf of the DORIPEX Study Group. Troya J, et al. Medicine (Baltimore). 2022 Jun 17;101(24):e29252. doi: 10.1097/MD.0000000000029252. Medicine (Baltimore). 2022. PMID: 35713430 Free PMC article.
Risk factors of severe hepatotoxicity among HIV-1 infected individuals initiated on highly active antiretroviral therapy in the Northwest Region of Cameroon.
Abongwa LE, Nyamache AK, Charles F, Torimiro J, Emmanuel N, Domkam I, Eyongetah M, Jude B, Mua FH, Bella S, Tamboh TC, Moungang EC, Ngum V, Okemo P. Abongwa LE, et al. BMC Gastroenterol. 2022 Jun 3;22(1):286. doi: 10.1186/s12876-022-02305-x. BMC Gastroenterol. 2022. PMID: 35658835 Free PMC article.
Associations of modern initial antiretroviral drug regimens with all-cause mortality in adults with HIV in Europe and North America: a cohort study.
Trickey A, Zhang L, Gill MJ, Bonnet F, Burkholder G, Castagna A, Cavassini M, Cichon P, Crane H, Domingo P, Grabar S, Guest J, Obel N, Psichogiou M, Rava M, Reiss P, Rentsch CT, Riera M, Schuettfort G, Silverberg MJ, Smith C, Stecher M, Sterling TR, Ingle SM, Sabin CA, Sterne JAC. Trickey A, et al. Lancet HIV. 2022 Jun;9(6):e404-e413. doi: 10.1016/S2352-3018(22)00046-7. Lancet HIV. 2022. PMID: 35659335 Free PMC article.
Combination anti-HIV antibodies provide sustained virological suppression.
Sneller MC, Blazkova J, Justement JS, Shi V, Kennedy BD, Gittens K, Tolstenko J, McCormack G, Whitehead EJ, Schneck RF, Proschan MA, Benko E, Kovacs C, Oguz C, Seaman MS, Caskey M, Nussenzweig MC, Fauci AS, Moir S, Chun TW. Sneller MC, et al. Nature. 2022 Jun;606(7913):375-381. doi: 10.1038/s41586-022-04797-9. Epub 2022 Jun 1. Nature. 2022. PMID: 35650437 Free PMC article. Clinical Trial.
Efficacy and safety of dolutegravir or darunavir in combination with lamivudine plus either zidovudine or tenofovir for second-line treatment of HIV infection (NADIA): week 96 results from a prospective, multicentre, open-label, factorial, randomised, non-inferiority trial.
Paton NI, Musaazi J, Kityo C, Walimbwa S, Hoppe A, Balyegisawa A, Asienzo J, Kaimal A, Mirembe G, Lugemwa A, Ategeka G, Borok M, Mugerwa H, Siika A, Odongpiny ELA, Castelnuovo B, Kiragga A, Kambugu A; NADIA Trial Team. Paton NI, et al. Lancet HIV. 2022 Jun;9(6):e381-e393. doi: 10.1016/S2352-3018(22)00092-3. Epub 2022 Apr 20. Lancet HIV. 2022. PMID: 35460601 Free article. Clinical Trial.
Reversibility of Central Nervous System Adverse Events in Course of Art.
Taramasso L, Orofino G, Ricci E, Menzaghi B, De Socio GV, Squillace N, Madeddu G, Vichi F, Celesia BM, Molteni C, Conti F, Del Puente F, Sarchi E, Angioni G, Cascio A, Grosso C, Parruti G, Di Biagio A, Bonfanti P; CISAI Study Group. Taramasso L, et al. Viruses. 2022 May 11;14(5):1028. doi: 10.3390/v14051028. Viruses. 2022. PMID: 35632768 Free PMC article.
Kidney function in tenofovir disoproxil fumarate-based oral pre-exposure prophylaxis users: a systematic review and meta-analysis of published literature and a multi-country meta-analysis of individual participant data.
Schaefer R, Amparo da Costa Leite PH, Silva R, Abdool Karim Q, Akolo C, Cáceres CF, Dourado I, Green K, Hettema A, Hoornenborg E, Jana S, Kerschberger B, Mahler H, Matse S, McManus H, Molina JM, Reza-Paul S, Azwa I, Shahmanesh M, Taylor D, Vega-Ramirez H, Veloso VG, Baggaley R, Dalal S. Schaefer R, et al. Lancet HIV. 2022 Apr;9(4):e242-e253. doi: 10.1016/S2352-3018(22)00004-2. Epub 2022 Mar 7. Lancet HIV. 2022. PMID: 35271825 Free PMC article.
Bone mineral density, kidney function and participant-reported outcome measures in women who switch from tenofovir disoproxil emtricitabine and a nonnucleoside reverse transcriptase inhibitor to abacavir, lamivudine and dolutegravir.
Campbell L, Ibrahim F, Barbini B, Samarawickrama A, Orkin C, Fox J, Waters L, Gilleece Y, Tariq S, Post FA; BESTT Trial Team*,†. Campbell L, et al. HIV Med. 2022 Apr;23(4):362-370. doi: 10.1111/hiv.13215. Epub 2021 Dec 5. HIV Med. 2022. PMID: 34866304 Free article. Clinical Trial.
Pharmacokinetics and Safety of the Abacavir/Lamivudine/Lopinavir/Ritonavir Fixed-Dose Granule Formulation (4-in-1) in Neonates: PETITE Study.
Bekker A, Rabie H, Salvadori N, du Toit S, Than-In-At K, Groenewald M, Andrieux-Meyer I, Kumar M, Cressey R, Nielsen J, Capparelli E, Lallemant M, Cotton MF, Cressey TR; PETITE Study Team. Bekker A, et al. J Acquir Immune Defic Syndr. 2022 Mar 1;89(3):324-331. doi: 10.1097/QAI.0000000000002871. J Acquir Immune Defic Syndr. 2022. PMID: 34855626 Free PMC article. Clinical Trial.
2,674 results